Viridian Therapeutics Announces Incentive Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the Company’s Board of Directors have approved the grant of non-qualified stock options to purchase an aggregate of 173,000 shares of the Company’s common stock to five new employees (the “Inducement Grants”) on September 3, 2024 (the “Grant Date”). The Inducement Grants were made outside of the Company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”), but remain subject to the terms and conditions of that Plan. The Inducement Grants were provided as an incentive to these individuals who joined Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants have an exercise price per share equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the first anniversary of the employee’s start date, and the remainder of the shares vesting in 36 equal monthly installments thereafter, subject to each employee’s continued employment with Viridian through the applicable grant dates.